The adaptive immune system uses several strategies to generate a repertoire of T- and B-cell
antigen receptors with sufficient diversity to recognize the universe of potential pathogens. …

Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types 1 , 2 , 3 , 4 , 5 . One …

Diversity in T lymphocyte antigen receptors is generated by somatic rearrangement of T cell
receptor (TCR) genes and is concentrated within the third complementarity-determining …

The tumor suppressor p53 gene is mutated in minimally half of all cancers. It is therefore
reasonable to assume that naturally occurring polymorphic genetic variants in the p53 stress …

T cell responses to allogeneic major histocompatibility complex antigens present a formidable
barrier to organ transplantation, necessitating long-term immunosuppression to minimize …

An individual's T cell repertoire dynamically encodes their pathogen exposure history. To
determine whether pathogen exposure signatures can be identified by documenting public T …

Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor
antigens targeted in successful treatments remain poorly defined. We used a personalized …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

T and B cell receptor loci undergo combinatorial rearrangement, generating a diverse
immune receptor repertoire, which is vital for recognition of potential antigens. Here we use a …

Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce
durable responses in a substantial fraction of melanoma patients. We sought to determine …